Improvements in Frailty Care as Cost Effective

By Staff Writer

January 15, 2024

Frailty care improvements

Frail patients require a robust system during hospital admission to decrease deconditioning risk and hasten discharge. In recent years, a significant effort has gone into quickly identifying these patients. Specialists evaluate them as part of a Frailty Liaison Team. This study examines the effect of these metrics on patient outcomes, as published in the Future Healthcare Journal. 

The Importance of Locating and Transferring Patients at an Early Stage

According to the findings of previous research, proposed internal transfers frequently face delays or may not take place at all. In 2017, hospitals moved three-fifths of fragile patients to appropriate wards. These delays likely influence the duration of hospital stays. This assumption is based on the specialised care frailty units provide. 

A Discussion of the Research Methodology

The Frailty Liaison Team performs the Comprehensive Geriatric Assessment (CGA) on patients classified as frail. These patients receive treatment on the Clinical Decisions Unit (CDU) or the Acute Medical Unit (AMU). This study compares the length of stay for patients transferred to a frailty ward on the assessment day with those transferred after 24 hours. 

The findings of the research study

According to the findings of the study, early transfers result in a hospital stay that is reduced by more than one day. This results in a reduction in direct costs as well as a reduction in the patient’s exposure toward harm that is associated with the hospital. According to this study frailty care improvements could lead to potential annual saving of £26,640.

The Consequences That the Study Could Have

Because of the favourable findings of the study, conversations have begun regarding the possibility of improving the local frailty route. The authors will use the data to identify potential improvements in patient care and compare different discharge procedures. 

The findings of this study emphasise the need of identifying frail individuals at an early stage and transferring them to specialised wards to receive treatment. They have the potential to greatly enhance patient outcomes while also lowering the expense of healthcare. 

 

Reference url

Recent Posts

340B Drug Pricing Lawsuit
      

Lawsuits Challenge 340B Drug Pricing Program: Eli Lilly and J&J vs. HRSA

🤔 How will ongoing legal battles shape the future of the 340B Drug Pricing Program?

Eli Lilly and Johnson & Johnson are challenging HRSA’s proposed rebate models, arguing that their approaches are essential for enhancing transparency and ensuring discounts directly benefit vulnerable patients. This crucial legal dispute highlights the tensions surrounding drug pricing regulations and could profoundly impact how discounts are provided to covered entities.

Dive into the details of these lawsuits and their implications for the pharmaceutical landscape.

#SyenzaNews #pharmaceuticals #healthcarepolicy #innovation #DrugPricing

WHO Investment Round 2023
    

WHO Investment Round: Securing Funding with Transparency Challenges

🌍 How can global health initiatives thrive with increased funding?

The WHO Investment Round is a pivotal initiative striving to secure $7.1 billion for essential health programs from 2025 to 2028. While achieving 53% of this target via diverse donor engagement, transparency in funding remains a challenge. Discover how these efforts can accelerate progress towards universal health coverage and tackle critical health issues like malaria and cervical cancer!

#SyenzaNews #globalhealth #universalhealthcoverage #healthcare #innovation

HPV vaccination South Africa
    

HPV vaccination South Africa: Cervical Cancer Prevention

🌍 How is South Africa leading the charge against cervical cancer?

Since launching its HPV vaccination program, the country has made remarkable strides in protecting future generations. With impressive coverage rates and a focus on at-risk populations, South Africa serves as a global model for effective public health strategies. Discover how this initiative not only combats cervical cancer but also addresses broader health concerns.

#SyenzaNews #HealthTech #GlobalHealth #HealthcareInnovation #CervicalCancer #HPVVaccination

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.